Role of the plasma level of plasminogen activator inhibitor type-1 (PAI-1) and genetic polymorphism of <i>PAI-1</i> gene in patients with ischemic heart disease in Uzbek population

Aim – to study the distribution of allele frequencies of the polymorphic marker 4G(-675)5G of the PAI-1 gene among patients with coronary heart disease and individuals with risk factors for the development of coronary heart disease. Material and methods. The study included 63 patients with diagnosed coronary heart disease, especially with stable angina (48 men and 15 women) hospitalized in the 1st Cardiology Department of the Multidisciplinary Clinic of the Tashkent Medical Academy. The average age of patients was 56.8 ± 6.40 years (42-66 years old). The state of hypercoagulability was assessed by measures of polymorphism gene of PAI-1 and plasma level of PAI-1. Results. The assessment of the frequency of various variants of the 4G(-675)5G polymorphic marker of the PAI-1 gene showed that differences in the distribution of the 5G/5G, 4G/5G, 4G/4G genotypes depending on the functional class of coronary artery disease are not statistically significant, since the chi-square test value was χ2 = 1.85 (p 0.05). Based on the obtained results, it can be assumed that the presence of hetero- and homozygous variants of the 4G allele of the PAI-1 gene does not affect the severity of the disease, in particular, the functional class of stable angina. Conclusion. The 4G/5G polymorphism of the PAI-1 gene was significantly associated with the risk of coronary heart disease in the Uzbek population. When stratified by angina functional class, the results showed that the 4G/5G polymorphism is associated with an increased risk of coronary heart disease and higher plasma PAI-1 levels.

Not yet translated